Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytotec Relabeling Adds Labor Section; Mifeprex “Dear Doctor” Letter Sent

Executive Summary

FDA is requiring Pharmacia to re-label Cytotec (misoprostol) to reflect use with Danco's Mifeprex without explicitly addressing the abortifacient regimen

You may also be interested in...

Searle/FDA Cytotec Labeling Negotiations Continue Ahead Of Mifeprex Launch

FDA is continuing to negotiate with Searle regarding changes to labeling of its gastric ulcer treatment Cytotec (misoprostol), which is an essential component of the recently approved Mifeprex (mifepristone, RU-486) regimen for termination of pregnancy.

Searle Cytotec

"Special considerations" boxed warning added to misoprostol labeling in order to strengthen contraindication in pregnancy. Labeling has also been updated to include reports of serious adverse events associated with use of Cytotec in pregnant women (1"The Pink Sheet" Aug. 28, p. 14)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts